Adial Pharmaceuticals (ADIL) Financials

Adial Pharmaceuticals (NASDAQ: ADIL) remains a development-stage biotechnology company with no reported revenue. Revenue has been listed at $0 in every income statement period provided, so the company continues to rely on financing and its cash reserves to fund operations and research.

Operating losses remain persistent, although they have improved from some earlier periods. Net loss was $2.02 million in Q1 2026, compared with $2.00 million in Q4 2025, $2.23 million in Q1 2025 and $2.46 million in Q2 2024. Q1 2026 operating expenses increased to $2.00 million from $1.89 million in Q4, as selling, general and administrative expense rose to $1.57 million. Research and development expense declined to $433,000 from $619,000 in Q4.

Cash flow shows a similar pattern: Adial used $1.61 million in operating cash during Q1 2026, following quarterly operating outflows of $1.32 million in Q4 2025, $1.83 million in Q3 and $1.75 million in Q2. The company generated no investing cash flow in Q1 2026 and raised $315,000 through common equity issuance, resulting in a net cash decrease of $1.30 million.

• Cash and equivalents totaled $4.58 million at March 31, 2026. The balance is substantially higher than the $2.37 million reported at March 31, 2025, providing a larger liquidity base than the company had one year earlier.
• The balance sheet remains lightly leveraged. Total liabilities were $1.51 million, with no noncurrent liabilities, compared with total equity of $3.72 million. This limits near-term debt-related pressure.
• Current liquidity is relatively strong. Current assets of $4.80 million exceeded current liabilities of $1.51 million by roughly 3.2 times, although much of that liquidity is being consumed by operations.
• Quarterly net losses have generally improved from the unusually large Q1 2024 loss of $6.48 million. Recent losses have remained near $2 million per quarter, suggesting some stabilization in the expense base even though profitability is not yet close.
• Research and development spending has declined. Q1 2026 R&D expense of $433,000 was below $733,000 in Q2 2025 and $747,000 in Q1 2025. This may conserve cash, but it could also indicate reduced development activity; the financial statements alone do not establish the reason.
• Long-term investments fell to $422,000 from $1.09 million in Q3 2024. The reduction may have increased cash availability, but it also leaves the company with fewer investment assets outside its operating cash balance.
• Adial has no operating revenue and continues to generate substantial losses. With zero revenue and a $2.00 million operating loss in Q1 2026, the company has not demonstrated a self-sustaining business model.
• Operating cash burn remains high. The company used $1.61 million in operating cash in Q1 2026. At a similar burn rate, the $4.58 million cash balance represents roughly three quarters of operating runway before considering changes in spending, financing or other cash resources.
• The company remains dependent on equity financing. Financing inflows supported cash in prior periods, including $5.30 million in Q2 2025 and $2.60 million in Q4 2025. Q1 2026 financing of $315,000 was not enough to offset operating cash use, increasing the risk of future capital raises.
• Shareholder dilution has been significant. Weighted-average basic shares increased from 261,590 in restated Q1 2025 to 1.37 million in Q1 2026, while Q3 2025 reported 22.17 million shares. The inconsistent share counts reflect major capital structure changes and make per-share comparisons difficult, but repeated equity issuance remains a material risk for existing investors.

Overall, ADIL’s financial position is supported by cash and limited debt, but the trend remains speculative. The company has enough liquidity to continue near-term operations based on the reported balance sheet, yet ongoing operating losses, zero revenue and recurring reliance on equity financing create a meaningful risk of additional dilution. Investors should closely monitor cash burn, clinical or commercialization progress, and the terms of any future financing.